Vertex is laying off 125 employees in Rhode Island and consolidating offices, following the discontinuation of a Type 1 ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...

GSK GSK0.87%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with ...

The treatment, made by Boston Pharmaceuticals, is ready to enter the last stage of clinical tests, the UK drugmaker said Wednesday. The medicine could become a blockbuster, according to analysts ...